Will Covid-19 vaccines bring life back to normal in 2021?
Vaccinating tens of millions of people will be very difficult
Three vaccine breakthroughs have sparked hope that the end of the Covid-19 pandemic is close. But vaccinating tens of millions of South Africans is going to be difficult. It would require a massive logistical effort in 2021 for life to return to the way it was before Covid-19.
We now have effective Covid vaccines from Pfizer/BioNTech, Moderna, and Oxford/AstraZeneca. None have yet been approved by medical authorities and the study results have not yet been published in peer-reviewed journals, but this is imminent.
If we want life to go back to the way it was in February 2020, we will have to vaccinate tens of millions of South Africans next year to squash the epidemic. This is a very tall order. No vaccine in South Africa has ever been administered to anything like that many people in such a short period of time.
It may be more realistic to protect people most at risk: health workers, older people and people with diabetes. That wouldn’t suppress the epidemic, nor would it return life to pre-Covid. Masks, sanitisers and physical distancing would still be necessary. But it would reduce the number of deaths and make the health system more manageable.
Does our health system do anything on a similar scale?
South Africa has good vaccination programmes. We vaccinate about a million children every year. 86% of children were vaccinated against measles according to a 2016 StatsSA report.
In a national drive in 2014, over 350,000 girls received the Human Papilloma Vaccine (HPV) in one month at 16,000 public schools.
This is impressive, but it’s nowhere near the scale of tens of millions of vaccine doses needed to suppress the country’s Covid-19 epidemic.
Our vaccine programmes also have difficulties. In an analysis of the 2014 HPV drive, thousands of doses were reported damaged or broken, and keeping the vaccines cold and properly stored was a major challenge. Worryingly, there was also a large-scale disinformation campaign launched against the HPV campaign, particularly in Mpumalanga.
The HPV vaccine in 2014 was delivered in two doses. Likewise, all three Covid vaccines require two jabs (a few weeks apart). If we aim to end the epidemic, tens of millions of people will have to keep their second appointment.
There are some even bigger health programmes in the country that offer hope. Millions of South African women regularly obtain birth control in the public health system. About five million people with HIV receive their antiretrovirals every few months; it’s probably the largest public sector chronic medication programme in the world. Many of those five million also get a viral load test once a year — which means getting blood drawn using a needle and getting the result back. But although this is huge, it is still not comparable to the scale of the vaccine programme needed to eradicate Covid-19.
It is not impossible to roll-out immunisation at mass-scale, as India’s polio eradication programmes can attest. Since 1995, India has held two National Immunisation Days (NIDs) each year. On the first two NIDs, on December 9, 1995 and January 20, 1996, 87 million children up to 3 years old were reached. The following year, 125 million children up to 5 years old were immunised.
Can the influenza vaccine offer a model of how to do it? In South Africa we typically vaccinate about a million people a year against the flu, and apparently aimed for 2 million this year; that’s not bad, but it’s far from what’s needed for Covid immunity. It’s also only one jab. (The UK has been trying to vaccinate 30 million people against the flu this year, which will be an impressive feat if achieved.)
Could we at least aim to vaccinate tens of millions of people over two, three or four years against Covid? Perhaps, but we don’t know yet if any of the vaccines remain effective for that long.
Keeping it cold
Two of the three Covid-19 vaccines have very difficult storage requirements. The Pfizer vaccine has to be stored at extremely low temperatures: it is stable for six months when stored at -80°C. You need special freezers for that. The vaccine must be transported in boxes filled with dry-ice that should only be opened twice a day. It expires two hours after thawing.
Moderna’s vaccine must ideally be kept at about -20°C (still much lower than a standard freezer), and will remain stable at that temperature for six months. A 16 November press release announced that new results indicated that this vaccine can be kept in a fridge for up to 30 days, and at room temperature for up to 12 hours.
The Oxford vaccine, which also has the lowest price, has the most manageable cold storage requirements. This vaccine only requires storage in a fridge (at 2 to 8°C), and will remain stable at these temperatures for at least six months.
How effective are the vaccines?
All three are very effective, if the results have been properly reported and the studies have been well conducted. Moderna reported that 95% of people who got the vaccine had an immune response that protects them from acquiring the virus. Pfizer reported 90%, and Oxford 70%.
The results do not mean that Moderna’s vaccine is more effective than Pfizer’s or that Pfizer’s is more effective than Oxford’s. They were tested in different trials in different populations, and in different doses even within the same trial. We’ll need more data before being able to compare vaccines.
Competing for the vaccine against the rest of the world
Pfizer says 50 million doses will be available by the end of 2020, and 1.3 billion doses will be produced by the end of 2021.
AstraZeneca claims that it will be able to produce 3 billion doses (of the Oxford vaccine) by the end of 2021.
Moderna says it can produce 20 million doses in 2020, and between 500 million and one billion doses in 2021.
There are about 8 billion people on the planet and there will be a lot of competition for those doses.
South Africa has vaccine manufacturing capacity. Aspen Pharmacare has reached an agreement with Johnson & Johnson to produce its candidate vaccine, pending results. It can produce 300 million doses a year at its plant in Port Elizabeth.
Biovac, of which the state owns a minority stake, claims it is currently capable of producing between 20 million and 30 million doses of a vaccine a year. It is currently in discussions with vaccine companies.
Also, the fact that South Africa was a testing site for the Pfizer vaccine may mean we have some leverage there.
According to reports, the United Kingdom government has ordered 100 million doses of the Oxford vaccine, and 40 million doses of the Pfizer one (for both vaccines, a patient requires two doses). Australia has ordered 33.8 million Oxford vaccine doses. The European Union has ordered 400 million doses of the Oxford vaccine.
Developing world access to the Oxford vaccine appears, at present, to now total 500 million doses, administered through the COVAX partnership.
South Africa has not at present formally signed up to COVAX, according to reports in the Daily Maverick. Bhekisisa has published an overview of COVAX, and what it means.
The cost of each vaccine varies widely. According to the Financial Times, the Oxford vaccine is the cheapest at $3-$4 (R45-R61) a dose. The cost of one dose of Moderna’s vaccine is reported to be $37 (R565), while one dose of Pfizer’s is $20 (R305).
Vaccinating tens of millions of people will cost several billion rand for the doses alone. On 24 November Finance Minister Tito Mboweni announced the allocation of R500 million to “participate in the process of the production of the vaccine”, and that the state is prepared to spend R5 billion to access vaccines. This may seem like a lot of money but it will almost certainly be offset by saved health-care costs, let alone the many benefits of a more open economy.
Who gets the vaccine first?
Who should be prioritised for the vaccine is still being debated around the world. In South Africa, the three to four hundred thousand health workers should arguably be first in line. There are between three and four million people over the age of 65, and perhaps they could come next.
Even reaching this most vulnerable part of the population next year would be a considerable undertaking. The rollout of this needs to be planned now.
Meanwhile most of us will have to keep on taking measures to avoid infection. Don’t plan to throw your masks in the fire anytime soon.
Dodgy people are suing us. Please support us by contributing to our legal costs and helping us to publish news that matters.
Next: Thousands of health workers march for permanent employment
Previous: Union slams public works programme
The SA vaccine programme has a number of shortcomings – looking at national coverage is often misleading. A quick look at the provincial 1-year immunisation coverage reveals that four provinces (Free State, Eastern Cape, North West and Limpopo) have coverage rates far below the 80% WHO (and SA) target (District Health Barometer 2018/9). Further drilling down shows that nine districts fall below the 79% coverage rate. This, in a middle-income country, is really unacceptable.
In relation to COVID-19 vaccination, the target will largely be adults for whom there isn't a national programme, so reaching them will be so much harder. Apart from getting fewer doses than we will need, one look at the influenza programme doesn't make the COVID vaccination look very encouraging. There are ways to increase demand and improve services but, in the past, the DOH has not invested in communication and social mobilisation around immunisation. Perhaps they will this time but, in the era of shortage of money, communication seems to be the first thing that falls off the agenda.
© 2020 GroundUp. This article is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
You may republish this article, so long as you credit the authors and GroundUp, and do not change the text. Please include a link back to the original article.